Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Interest Expense

: $-1,166 Mil (TTM As of Dec. 2023)

View and export this data going back to 1952. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Bristol-Myers Squibb Co's interest expense for the three months ended in Dec. 2023 was $ -316 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-1,166 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Bristol-Myers Squibb Co's Operating Income for the three months ended in Dec. 2023 was $ 1,903 Mil. Bristol-Myers Squibb Co's Interest Expense for the three months ended in Dec. 2023 was $ -316 Mil. Bristol-Myers Squibb Co's Interest Coverage for the quarter that ended in Dec. 2023 was 6.02. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Bristol-Myers Squibb Co Interest Expense Historical Data

The historical data trend for Bristol-Myers Squibb Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-656.00

-1,420.00

-1,334.00

-1,232.00

-1,166.00

Bristol-Myers Squibb Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense																-294.00	-288.00	-282.00	-280.00	-316.00

Bristol-Myers Squibb Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,166 Mil.

Bristol-Myers Squibb Co (NYSE:BMY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Bristol-Myers Squibb Co's Interest Expense for the three months ended in Dec. 2023 was $-316 Mil. Its Operating Income for the three months ended in Dec. 2023 was $1,903 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $38,183 Mil.

Bristol-Myers Squibb Co's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	1903	/	-316
	=	6.02

The higher the ratio, the stronger the company's financial strength is.

Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:Peru BMY:Mexico 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BRM:Germany BRM:Germany BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

430 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Executives

Christopher S. Boerner	officer: EVP, Chief Commercial Officer	21823 30TH DRIVE S, BOTHELL WA 98021
Samuels Theodore R. Ii	director	1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman	officer: EVP, Corporate Affairs	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge	officer: SVP, Human Resources	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge	officer: EVP, Chief Research Officer	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey	officer: Pres., Research & Early Dev.	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky	officer: EVP, Chief Commercial Officer	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio	officer: EVP & Chief Commercial Officer	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins	officer: EVP, Chief Financial Officer	C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt	director	BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung	officer: Vice President and Secretary	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees	officer: SVP & Controller	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan	officer: EVP, Glob. Prod. Dev. & Supply	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers	officer: EVP, Chief Digital & Tech Off.	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Autenried Paul Von	officer: SVP, Enterp. Services & CIO	BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543